[96a5a0]: / output / allTrials / identified / NCT01048320_identified.json

Download this file

390 lines (390 with data), 16.1 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
{
"info": {
"nct_id": "NCT01048320",
"official_title": "A Phase I Study of Gemcitabine Plus Oxaliplatin in Combination With Imatinib Mesylate (Glivec) in Patients With Gemcitabine-refractory Advanced Adenocarcinoma of the Pancreas",
"inclusion_criteria": "* age > 18 years\n* gemcitabine-refractory, histologically confirmed pancreatic cancer (progression during or within 6 months of first-line treatment)\n* locally advanced or metastatic disease with measurable or non-measurable disease\n* life expectancy of greater than 10 weeks\n* prior treatment with investigational therapies including EGFR and VEGF antagonists is allowed when administered>4 weeks prior to start of therapy\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* any serious uncontrolled medical condition\n* prior radiation treatment is not allowed\n* no prior chemotherapy within the previous 4 weeks\n* known peripheral neuropathy > CTCAE v 3.0 grade 1; absence of the deep tendon reflexes as the sole neurological abnormality does not render the patient ineligible\n* known brain metastases\n* lack of physical integrity of the upper GI tract, malabsorption syndrome, or inability to take oral medication\n* fertile women (<2 years after last menstruation) and men of childbearing potential not willing to use effective contraception\n* pregnancy or breast feeding",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* age > 18 years",
"criterions": [
{
"exact_snippets": "age > 18 years",
"criterion": "age",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": ">",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "* gemcitabine-refractory, histologically confirmed pancreatic cancer (progression during or within 6 months of first-line treatment)",
"criterions": [
{
"exact_snippets": "gemcitabine-refractory",
"criterion": "gemcitabine-refractory",
"requirements": [
{
"requirement_type": "status",
"expected_value": "refractory"
}
]
},
{
"exact_snippets": "histologically confirmed pancreatic cancer",
"criterion": "pancreatic cancer",
"requirements": [
{
"requirement_type": "confirmation method",
"expected_value": "histologically confirmed"
}
]
},
{
"exact_snippets": "progression during or within 6 months of first-line treatment",
"criterion": "progression after first-line treatment",
"requirements": [
{
"requirement_type": "time frame",
"expected_value": "during or within 6 months"
}
]
}
]
},
{
"line": "* locally advanced or metastatic disease with measurable or non-measurable disease",
"criterions": [
{
"exact_snippets": "locally advanced or metastatic disease",
"criterion": "disease stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": [
"locally advanced",
"metastatic"
]
}
]
},
{
"exact_snippets": "measurable or non-measurable disease",
"criterion": "disease measurability",
"requirements": [
{
"requirement_type": "measurability",
"expected_value": [
"measurable",
"non-measurable"
]
}
]
}
]
},
{
"line": "* life expectancy of greater than 10 weeks",
"criterions": [
{
"exact_snippets": "life expectancy of greater than 10 weeks",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">",
"value": 10,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* prior treatment with investigational therapies including EGFR and VEGF antagonists is allowed when administered>4 weeks prior to start of therapy",
"criterions": [
{
"exact_snippets": "prior treatment with investigational therapies",
"criterion": "prior treatment with investigational therapies",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "EGFR and VEGF antagonists",
"criterion": "prior treatment with EGFR and VEGF antagonists",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "administered>4 weeks prior to start of therapy",
"criterion": "time since last administration of investigational therapies",
"requirements": [
{
"requirement_type": "time since last administration",
"expected_value": {
"operator": ">",
"value": 4,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* any serious uncontrolled medical condition",
"criterions": [
{
"exact_snippets": "serious uncontrolled medical condition",
"criterion": "medical condition",
"requirements": [
{
"requirement_type": "control",
"expected_value": false
},
{
"requirement_type": "severity",
"expected_value": "serious"
}
]
}
]
},
{
"line": "* prior radiation treatment is not allowed",
"criterions": [
{
"exact_snippets": "prior radiation treatment is not allowed",
"criterion": "prior radiation treatment",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* no prior chemotherapy within the previous 4 weeks",
"criterions": [
{
"exact_snippets": "no prior chemotherapy within the previous 4 weeks",
"criterion": "prior chemotherapy",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* known peripheral neuropathy > CTCAE v 3.0 grade 1; absence of the deep tendon reflexes as the sole neurological abnormality does not render the patient ineligible",
"criterions": [
{
"exact_snippets": "known peripheral neuropathy > CTCAE v 3.0 grade 1",
"criterion": "peripheral neuropathy",
"requirements": [
{
"requirement_type": "severity",
"expected_value": {
"operator": ">",
"value": 1,
"unit": "CTCAE v 3.0 grade"
}
}
]
},
{
"exact_snippets": "absence of the deep tendon reflexes as the sole neurological abnormality",
"criterion": "deep tendon reflexes",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* known brain metastases",
"criterions": [
{
"exact_snippets": "known brain metastases",
"criterion": "brain metastases",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* lack of physical integrity of the upper GI tract, malabsorption syndrome, or inability to take oral medication",
"criterions": [
{
"exact_snippets": "lack of physical integrity of the upper GI tract",
"criterion": "physical integrity of the upper GI tract",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "malabsorption syndrome",
"criterion": "malabsorption syndrome",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "inability to take oral medication",
"criterion": "ability to take oral medication",
"requirements": [
{
"requirement_type": "ability",
"expected_value": true
}
]
}
]
},
{
"line": "* fertile women (<2 years after last menstruation) and men of childbearing potential not willing to use effective contraception",
"criterions": [
{
"exact_snippets": "fertile women (<2 years after last menstruation)",
"criterion": "fertile women",
"requirements": [
{
"requirement_type": "time since last menstruation",
"expected_value": {
"operator": "<",
"value": 2,
"unit": "years"
}
}
]
},
{
"exact_snippets": "men of childbearing potential",
"criterion": "men of childbearing potential",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "not willing to use effective contraception",
"criterion": "willingness to use effective contraception",
"requirements": [
{
"requirement_type": "willingness",
"expected_value": false
}
]
}
]
},
{
"line": "* pregnancy or breast feeding",
"criterions": [
{
"exact_snippets": "pregnancy",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "breast feeding",
"criterion": "breast feeding",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}